Working… Menu

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00499720
Expanded Access Status : Approved for marketing
First Posted : July 11, 2007
Last Update Posted : August 2, 2011
Information provided by:
Gilead Sciences

Brief Summary:
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Condition or disease Intervention/treatment
Cystic Fibrosis Pseudomonas Aeruginosa Airway Infection Drug: Aztreonam Lysine for Inhalation

Layout table for study information
Study Type : Expanded Access
Official Title: Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression

Intervention Details:
  • Drug: Aztreonam Lysine for Inhalation
    75 mg three times a day via inhalation for 28 days followed by 28 days off drug.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:

  • ≥ 6 years of age
  • Subject has CF as diagnosed by one of the following:

    • Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test
    • Two well characterized genetic mutations in the CFTR gene
    • Abnormal nasal potential difference with accompanying symptoms characteristic of CF
  • At high risk for disease progression as defined by one of the following subject populations:

    • First Cohort Criteria:

      • Those who are wait listed or eligible for lung transplant based on FEV1 criteria. Patients who have a level of lung function impairment consistent with lung transplantation criteria, but who are ineligible for transplantation for other reasons, can enroll in this program; or
      • Completed participation in CP-AI-006 (through Visit 20). Subjects who withdraw from CP-AI-006 prior to completing all courses of AZLI and all study visits will not be eligible for this protocol.
    • Second Cohort Criteria:

      • Meets first cohort criteria
      • FEV1 ≤ 40% predicted at the time of consent
    • Third Cohort Criteria:

      • Meets first or second cohort criteria
      • FEV1 ≤ 50% predicted at the time of consent

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:

  • Subjects with any serious or active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance with the protocol or dosing requirements
  • Subjects with hypersensitivity to any of the components of the drug product
  • Currently enrolled in another clinical trial
  • Pregnant or lactating females

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00499720

Show Show 65 study locations
Sponsors and Collaborators
Gilead Sciences
Layout table for additonal information
Responsible Party: Debra Cibene/Senior Clinical Research Associate, Gilead Sciences, Inc. Identifier: NCT00499720    
Other Study ID Numbers: EA-US-205-0111
First Posted: July 11, 2007    Key Record Dates
Last Update Posted: August 2, 2011
Last Verified: July 2011
Keywords provided by Gilead Sciences:
Cystic Fibrosis
Pseudomonas aeruginosa
airway infection
Aztreonam Lysine for Inhalation
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Pseudomonas Infections
Cystic Fibrosis
Respiratory Aspiration
Disease Attributes
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Respiration Disorders
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Anti-Bacterial Agents
Anti-Infective Agents